

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

ANTIGENICS INC /DE/
Form 8-K
November 25, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report
(Date of earliest event reported):

November 24, 2003

ANTIGENICS INC.
(Exact name of registrant as specified in its charter)

DELAWARE 000-29089 06-1562417

(State or other jurisdiction of (Commission file number) (I.R.S. Employer
incorporation of organization) Identification No.)

630 FIFTH AVENUE, SUITE 2100
NEW YORK, NEW YORK 10111
(Address of principal executive offices and zip code)

(212) 994-8200
(Registrant's telephone number, including area code)

Item 5. Other Events

On November 24, 2003, the Company announced that the US Food and Drug Administration (FDA) has lifted the partial clinical hold on the two Phase III clinical trials of the company's personalized cancer vaccine Oncophage(R) (HSPPC-96). The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this current report on Form 8-K.

Item 7. Financial Statements and Exhibits.

(c) Exhibits:

99.1 Press Release dated November 24, 2003

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANTIGENICS INC.

Date: November 24, 2003

By: /s/ Garo H. Armen

Garo H. Armen, Ph.D.
Chairman and Chief Executive Officer

EXHIBIT INDEX

The following designated exhibits are filed herewith:

Exhibits:

99.1

Press Release dated November 24, 2003